EnteroMedics' obesity device fails to measure up in US trial – again
This article was originally published in Clinica
Executive Summary
EnteroMedics' share price has plunged 56% after reporting that its Maestro weight-loss device failed, for the second time, to meet its primary endpoint in a pivotal trial. However, the firm still plans to file a premarket approval (PMA) application with the US FDA in the second quarter. It is taking solace in the fact there was significant weight loss in patients treated with the device compared with a control group receiving sham therapy – although the effects was not as large as EnteroMedics had hoped for.